|Articles|January 7, 2017

Ebola May Have Found Another Place to Hide Out: The Lungs

Author(s)Kristi Rosa

Researchers have found potential evidence that suggests Ebola may be able to replicate in the lungs of recovering patients.

Previously, the Ebola virus has been found to remain in patients’ semen a number of days after it can be detected in the blood. Now, it appears that the virus may have found another place to escape detection: the lungs.

Researchers from the National Institute for Infectious Diseases “Lazzaro Spallanzani,” (INMI) in Rome, Italy, have found evidence that suggests Ebola can actually replicate in the lungs of an individual recovering from the infection. Their findings, which can be found in PLOS Pathogens, may offer a better understanding of how Ebola is transmitted as well as provide insight into new approaches to treating the virus, which has claimed over 11,000 lives in West Africa.

The largest unprecedented outbreak of Ebola that the world has seen thus far occurred in West Africa between 2013 and 2016. Since then, researchers from around the world have been putting their efforts into controlling the virus by learning more about it. According to a recent press release, “Lab studies, animal studies, and observations of evacuated patients treated in Europe and the United States have suggested that Ebola might cause lung damage by replicating itself in lung tissue.” Despite these suggestions, there has not yet been concrete evidence to validate lung infections caused by Ebola.

In order to examine this potential link further, researchers from INMI took a closer look at one patient during treatment for and recovery from the virus; the patient was a healthcare worker who had been evacuated from West Africa to receive treatment in Rome.

In their study, the researchers compared the levels of viral RNA fragments—known to be linked to Ebola replication—in both the patient’s lungs and blood. They found that, “viral RNA and viral replication markers remained in the lungs for about five days after it was no longer detectable in the blood.”

This means that it’s possible that the virus was replicating within the lungs, a place where the RNA could remain longer than it could in the blood. The authors noted, however, that active replication was also possible due to the fact that “the presence of RNA for both total and replication markers” were found in the patient’s lungs.

The authors concluded, “We demonstrated a long persistence of EBOV replication markers within the respiratory tract, compared to plasma. This suggests a major role of the respiratory tissues in the pathogenesis of Ebola virus disease.”

Future studies will be needed in order to gain a stronger understanding of the potential link between lung infection and Ebola and whether this may actually be a factor when it comes to transmission among humans, according to the authors.

These findings come on the heels of Merck, Sharpe, and Dohme’s Ebola vaccine, which recently showed 100% effectiveness against the deadly virus. With researchers working around the globe in a collective effort to control the virus, there is hope that with greater understanding of its functionality, coupled with the assistance of an effective vaccine, if another Ebola outbreak occurs, the world will not be left defenseless.


Related to this article

FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.